This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
by Zacks Equity Research
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
by Zacks Equity Research
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
by Zacks Equity Research
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
by Zacks Equity Research
Olema Pharmaceuticals (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
by Zacks Equity Research
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.5% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Olema Pharmaceuticals, Inc. (OLMA) points to an 80.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Olema Pharmaceuticals, Inc. (OLMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 92% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Olema Pharmaceuticals, Inc. (OLMA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.